Difference between revisions of "Envelope glycoprotein gp41"
| Line 40: | Line 40: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1f23A.pdf ASAView] pdf |
| − | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1f23A.txt ASAView] txt |
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 08:03, 25 July 2007
| Template:Infobox header| Envelope glycoprotein gp41 | |
|---|---|
| Envelope glycoprotein gp41 | |
| Substrate peptide name | Envelope glycoprotein gp41 |
| Synonyms | gp41 |
| Determination type | In vitro |
| Source | HIV |
| Subcellular localization | HIV exterior membrane |
| Swissprot ID | P03378 |
| Reactive glutamines | Q51, Q52, Q66 |
| Reactive lysines | K77 |
| Substrate sequence | RAIEAQQHLLQL
GIKQLQARILA VERYLKDQQLL |
| Structure | 1F23 |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:7688299 |
| Notes | |
| Template:Infobox header | | |
